公开(公告)号：US20240180900A1

公开(公告)日：2024-06-06

申请号：US18493773

申请日：2023-10-24

Applicant: Arvinas Operations, Inc.

Inventor： Ronald PECK ,  Sarah Deborah CHIRNOMAS ,  Edward CHAN ,  Richard Walter GEDRICH ,  Elmer J. BERGHORN, Jr. ,  Jeanette Toni ALICEA ,  Lawrence B. SNYDER ,  SangHyun LEE ,  Taavi NEKLESA

IPC: A61K31/496 ,  A61K31/573 ,  A61K31/58 ,  A61P35/00

CPC classification number: A61K31/496 ,  A61K31/573 ,  A61K31/58 ,  A61P35/00

Abstract: This disclosure pertains to methods of treating prostate cancer in a subject, including prostate cancer comprising at least one somatic AR tumor mutation, such as metastatic prostate cancer, castrate-resistant prostate cancer, metastatic castrate-resistant prostate cancer, progressive metastatic castrate-resistant prostate cancer, castrate-sensitive prostate cancer, metastatic castrate-sensitive prostate cancer, prostate cancer naïve to novel hormonal agents (NHAs), metastatic prostate cancer naïve NHAs, castrate-resistant prostate cancer naïve to NHAs, castrate-sensitive prostate cancer naïve to NHAs, metastatic castrate-resistant prostate cancer naïve to NHAs, and metastatic castrate-sensitive prostate cancer naïve to NHAs, wherein the method comprises administering to a subject in need thereof a therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240066032A1

公开(公告)日：2024-02-29

申请号：US18489262

申请日：2023-10-18

Applicant: Arvinas Operations, Inc.

Inventor： Sarah Deborah CHIRNOMAS ,  Richard Walter GEDRICH ,  Ronald PECK ,  Ian Charles Anthony TAYLOR

IPC: A61K31/506 ,  A61K9/00 ,  A61K31/496 ,  A61K31/501 ,  A61K31/58 ,  A61P35/00

CPC classification number: A61K31/506 ,  A61K9/0053 ,  A61K31/496 ,  A61K31/501 ,  A61K31/58 ,  A61P35/00

Abstract: The present application relates to treating and/or preventing prostate cancer, including metastatic and/or castrate-resistant prostate cancer, in a subject in need of treatment having particular somatic AR tumor biomarker status, comprising administering a compound of Formula (I),




or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative, or prodrug thereof, wherein R1, R2, R3, X1, X2, X3, X4, and n are defined herein.

公开(公告)号：US20220184078A1

公开(公告)日：2022-06-16

申请号：US17548161

申请日：2021-12-10

Applicant: Arvinas Operations, Inc.

Inventor： Sarah Deborah CHIRNOMAS ,  Richard Walter GEDRICH ,  Ronald PECK ,  Ian Charles Anthony TAYLOR

IPC: A61K31/506 ,  A61K9/00 ,  A61K31/58 ,  A61P35/00 ,  A61K31/496 ,  A61K31/501

Abstract: The present application relates to treating and/or preventing prostate cancer, including metastatic and/or castrate-resistant prostate cancer, in a subject in need of treatment having particular somatic AR tumor biomarker status, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative, or prodrug thereof, wherein R1, R2, R3, X1, X2, X3, X4, and n are defined herein.